Arctic Bioscience Past Earnings Performance
Past criteria checks 0/6
Arctic Bioscience's earnings have been declining at an average annual rate of -26%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 10% per year.
Key information
-26.0%
Earnings growth rate
-16.2%
EPS growth rate
| Biotechs Industry Growth | 20.9% |
| Revenue growth rate | 10.0% |
| Return on equity | -17.6% |
| Net Margin | -134.8% |
| Next Earnings Update | 29 Aug 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Arctic Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 34 | -46 | 24 | 0 |
| 30 Sep 23 | 36 | -43 | 24 | 0 |
| 30 Jun 23 | 39 | -40 | 25 | 0 |
| 31 Mar 23 | 37 | -37 | 23 | 0 |
| 31 Dec 22 | 34 | -34 | 22 | 0 |
| 30 Sep 22 | 29 | -35 | 18 | 0 |
| 30 Jun 22 | 24 | -36 | 15 | 0 |
| 31 Mar 22 | 23 | -39 | 16 | 0 |
| 31 Dec 21 | 22 | -43 | 17 | 0 |
| 30 Sep 21 | 23 | -38 | 15 | 0 |
| 30 Jun 21 | 25 | -34 | 13 | 0 |
| 31 Mar 21 | 23 | -28 | 12 | 0 |
| 31 Dec 20 | 21 | -23 | 11 | 0 |
| 31 Dec 19 | 30 | -4 | 6 | 0 |
| 31 Dec 18 | 25 | -2 | 6 | 0 |
| 31 Dec 17 | 18 | -2 | 5 | 0 |
Quality Earnings: ABS is currently unprofitable.
Growing Profit Margin: ABS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABS is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.
Accelerating Growth: Unable to compare ABS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ABS has a negative Return on Equity (-17.6%), as it is currently unprofitable.